UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance
30 December 2025
1 min read

UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance

NEW YORK, December 30, 2025, 5:05 PM ET — After-hours

  • UnitedHealth shares rose in after-hours trading, outpacing a slightly weaker broader market.
  • Managed-care peers were mixed, with modest gains in Elevance and Humana and a dip in CVS Health.
  • The next major catalyst is UnitedHealth’s late-January results and 2026 outlook update.

UnitedHealth Group shares were up about 1% at $332.16 in after-hours trading on Tuesday, following the 4 p.m. close. The stock ranged from $329.18 to $336.03 during the day’s session, with about 4.4 million shares traded.

The gain came as U.S. stocks ended slightly lower in holiday-thin trading. The S&P 500 slipped 0.14%, the Dow fell 0.20% and the Nasdaq lost 0.23%. Reuters

Investors are repositioning as 2025 winds down, and swings can look sharper when volumes are light. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Why it matters now for UnitedHealth is what comes next, not just where it traded in a single session. The company has set late January as the next key checkpoint for updated outlook and management commentary.

UnitedHealth said it will release full-year 2025 financial results and provide 2026 guidance on Tuesday, Jan. 27, before the market opens, and host a conference call at 8 a.m. ET. UnitedHealth Group

Among big managed-care names, the tape was steadier than UnitedHealth’s move. Elevance Health was up 0.1% and Humana gained 0.3%, while CVS Health, whose pharmacy-benefits manager negotiates drug prices for health plans, fell 0.2%.

Healthcare broadly lagged the single-stock move. The Health Care Select Sector SPDR Fund, an exchange-traded fund (ETF) that tracks major U.S. healthcare companies, was down 0.1%.

For investors, the late-January update will be a test of whether cost pressures are easing and how UnitedHealth is pricing for 2026. Managed-care stocks have been sensitive to signals around Medicare Advantage, the privately run alternative to the federal Medicare program for seniors.

A key watchpoint is the medical cost ratio, which shows how much premium revenue an insurer spends on medical claims. When that ratio rises, it can pinch profit margins even if membership grows.

Traders will also parse updates from Optum, UnitedHealth’s health-services business, for signs that services growth can offset pressure in the insurance unit. Any comments on utilization trends and pricing discipline are likely to set the tone for the group.

Ahead of the next session, investors expect thin liquidity to persist into year-end, when index and portfolio rebalancing can amplify moves. UnitedHealth’s outperformance versus the broader healthcare ETF on Tuesday underscored how quickly money can rotate inside the sector when market leadership shifts.

Stock Market Today

  • Walmart-backed PhonePe gets SEBI approval for India IPO
    January 20, 2026, 5:04 AM EST. Walmart-backed Indian payments firm PhonePe has secured regulatory approval from SEBI, India's market regulator, for its initial public offering (IPO). Confidential filings began in September. Major investors including Walmart, Microsoft, and Tiger Global plan to sell part of their holdings. PhonePe dominates the Indian payments space with over 45% market share on the Unified Payments Interface (UPI), processing 9.8 billion transactions in August 2025. It serves 600 million users and 50 million merchants. Despite losses narrowing to 17.2 billion rupees in fiscal 2025 from 19.96 billion rupees in 2024, PhonePe is capitalizing on India's robust IPO environment, which has seen record fundraising in 2025.
AppLovin stock slips after Fed minutes as year-end tech rotation hits APP shares
Previous Story

AppLovin stock slips after Fed minutes as year-end tech rotation hits APP shares

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus
Next Story

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Go toTop